A Phase 1 interventional study of Erlotinib and Erlotinib in Non-Small Cell Lung Cancer, sponsored by Pfizer. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 23 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 109th largest by enrollment of the 136 interventional ones that give a count, is one of 7 that started in 2010, is one of 56 in phase 1, and was the 42nd registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
2 of the studies testing crizotinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Erlotinib
Drug: Erlotinib · Drug: PF-02341066
Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)
Phase 1, first cycle DLT includes Grade (Gr) ≥4 hematologic possible drug-related toxicities and Gr ≥3 possible drug-related febrile neutropenia. Gr ≥3 non-hematological possible drug-related toxicities (except asymptomatic lab value elevation). Gr 3/4 nausea, vomiting or diarrhea. Gr 3 hypertension considered DLT if event unmanageable by approved pharmacologic agents or symptomatic sequelae despite medical intervention. Diagnosis of interstitial lung disease. Inability to deliver at least 80 percent (%) of planned dose during cycle 1 due to possible drug-related adverse events (AEs).
Time frame: Baseline up to Day 28
Progression-Free Survival (Phase 2)
Time in weeks from phase 2 study randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).
Time frame: Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity
PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)
AUCtau is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
Time frame: Cycle 1 (C1) Day 1 (D1) i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1)
Cmax is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib
Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1)
Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, It is used to characterize PF-02341066 CL/F after multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
Time frame: C1D15 i.e., 15 days of giving crizotinib and erlotinib
PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)
AUCtau is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1)
Cmax is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Molecular Weight Adjusted PF-06260182-to-PF-02341006 Ratio of AUCtau (Phase 1)
Molecular weight adjusted PF-06260182-to-PF-02341006 ratio of AUCtau is a measure of how much PF-02341066 (parent drug) was converted to the metabolite PF-06260182 after PF-02341066 dosing. In this study, it is used to characterize the metabolite-to-parent ratio exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
Time frame: C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Erlotinib Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)
AUCtau is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).
Time frame: C1D-1 i.e., 1 day prior to initiation of continuous dosing of crizotinib; C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Erlotinib Maximum Observed Plasma Concentration (Cmax) (Phase 1)
Cmax is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).
Time frame: C1D-1 i.e., 1 day prior to initiation of continuous dosing of crizotinib; C1D1 i.e., 1 day of giving crizotinib and erlotinib; and C1D15, i.e., 15 days of giving crizotinib and erlotinib
Erlotinib Apparent Oral Clearance (CL/F) (Phase 1)
Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, it is used to characterize erlotinib CL/F after multiple doses in combination with PF-02341066 (Cycle 1 Day 15).
Time frame: C1D15 i.e., 15 days of giving crizotinib and erlotinib
Ratio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)
Ratio of adjusted means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.
Time frame: C1D-1 (i.e., 1 day prior to initiation of continuous dosing of crizotinib) to C1D15 (i.e., 15 days of giving crizotinib and erlotinib)
Ratio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)
Ratio of adjusted means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.
Time frame: C1D-1 (i.e., 1 day prior to initiation of continuous dosing of crizotinib) to C1D15 (i.e., 15 days of giving crizotinib and erlotinib)
Progression-Free Survival (Phase 1)
Time in weeks from phase 1 randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for PD), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).
Time frame: Baseline, every 42 days until disease progression or unacceptable toxicity
Duration of Response (Phase 1)
Median duration (50 percent \[%\]) of tumor response. Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.
Time frame: Baseline, every 42 days until disease progression or unacceptable toxicity
Percentage of Participants With Objective Response (Phase 1)
Percentage of participants during phase 1 with objective response based assessment of confirmed CR or confirmed PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.
Time frame: Baseline, every 42 days until disease progression or unacceptable toxicity
Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 1)
Levels of soluble protein biomarker c-MET was analyzed at Baseline and at Day 50.
Time frame: Baseline and Day 50 (Cycle 3, Day 1)
Plasma Level of Soluble Marker: Hepatocyte Growth Factor (HGF) Scatter Factor (Phase 1)
Time frame: Baseline and Day 50 (Cycle 3, Day 1)
Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 2)
Time frame: Baseline and Day 50 (Cycle 3, Day 1)
Plasma Level of Soluble Marker: HGF Scatter Factor (Phase 2)
Time frame: Baseline and Day 50 (Cycle 3, Day 1)
Duration of Response (Phase 2)
Median duration (50%) of tumor response. DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.
Time frame: Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity
Percentage of Participants With Confirmed CR, PR or Stable Disease (SD) at Phase 2
Percentage of participants during phase 2 with confirmed CR, confirmed PR or SD according to RECIST 1.1. Also known as Disease Control Rate (DCR). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions. SD: neither sufficient shrinkage or increase to qualify for PR or PD.
Time frame: Week 6 and Week 12
Percentage of Participants With Objective Response (Phase 2)
Percentage of participants during phase 2 with objective response based assessment of confirmed CR or confirmed PR according to RECIST (1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.
Time frame: Baseline, every 42 days up to 20 months, disease progression, or unacceptable toxicity
Overall Survival (OS) at Phase 2
Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.
Time frame: Baseline until death, up to 20 months
European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire (QLQ-C30) Score at Phase 2
Phase 2 EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
Time frame: Baseline and every 21 days, up to 20 months
EORTC Quality of Life Questionnaire -Lung Cancer 13 (QLQ-LC13) Score at Phase 2
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, neuropathy, alopecia, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.
Time frame: Baseline and every 21 days, up to 20 months
Plasma Concentration of PF-02341066 and Erlotinib (Phase 2)
Plasma concentration of PF-02341066 and erlotinib when administered in combination during phase 2
Time frame: Day 1 of cycles 1, 3, and 5 (i.e., up to 15 weeks) at 0 (pre-dose) and 2 to 6 hours post dose
Plasma Concentration of Erlotinib (Phase 2)
Plasma concentration of erlotinib when administered as a single agent during phase 2
Time frame: Day 1 of cycles 1, 3, and 5 (i.e., up to 15 weeks) at 0 hours (pre-dose)
Percentage of Participants With Mutations in Tumor Tissue (Phase 2)
Tumor tissue samples collected for molecular profiling were to be analyzed to assess Kirsten rat sarcoma (KRAS) mutations, mutations, amplification and expression of Epidermal Growth Factor Receptor (EGFR) and c-Met, and echinoderm microtubule-associated protein-like 4-anaplastic large cell receptor kinase (EML4-ALK) fusion in tumors.
Time frame: Screening
Maximum Tolerated Dose (MTD) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)
MTD: the combination dose level of PF-02341066 and erlotinib in which 0/6 or 1/6 participants experienced DLT after 28 days of treatment (Cycle 1) with the next higher dose level having at least 2/3 or 2/6 participants with DLT during Cycle 1 of treatment.
Time frame: Baseline up to 28 days (Cycle 1)
Recommended Phase 2 Dose (RP2D) of PF-02341066 When Administered in Combination With Erlotinib (Phase 1)
If no more than 1/6 participants presented with a DLT during Cycle 1 at the MTD, then this dose level was considered the RP2D. If \>1/6 participants experienced a DLT, then the previous lower level was considered the MTD and RP2D.
Time frame: Baseline up to 28 days (Cycle 1)
| Milestone | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Started | 7 | 20 |
| Completed | 0 | 0 |
| Not completed | 7 | 20 |
| Withdrew: Death | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Other | 7 | 15 |
Phase 1, first cycle DLT includes Grade (Gr) ≥4 hematologic possible drug-related toxicities and Gr ≥3 possible drug-related febrile neutropenia. Gr ≥3 non-hematological possible drug-related toxicities (except asymptomatic lab value elevation). Gr 3/4 nausea, vomiting or diarrhea. Gr 3 hypertension considered DLT if event unmanageable by approved pharmacologic agents or symptomatic sequelae despite medical intervention. Diagnosis of interstitial lung disease. Inability to deliver at least 80 percent (%) of planned dose during cycle 1 due to possible drug-related adverse events (AEs).
| participants | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1) | 2 | 3 |
Time in weeks from phase 2 study randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).
No measurements were reported for this outcome.
AUCtau is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
| ng*hr/mL | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D1 Crizotinib (N=7, 19) | 581.9 ± 49 | 400.3 ± 40 |
| C1D15 Crizotinib (N=5, 14) | 2274 ± 43 | 1720 ± 40 |
Cmax is a measure of the plasma exposure to PF-02341066. In this study, it is used to characterize PF-02341066 exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib
| ng/mL | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D1 Crizotinib (N=7, 19) | 86.75 ± 37 | 65.31 ± 50 |
| C1D15 Crizotinib (N=5, 14) | 251.0 ± 46 | 185.9 ± 40 |
Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, It is used to characterize PF-02341066 CL/F after multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
| L/hr | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1) | 88.02 ± 43 | 87.20 ± 40 |
AUCtau is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
| ng*hr/mL | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D1 PF-06260182 (N=7, 19) | 16.48 ± 58 | 14.03 ± 72 |
| C1D15 PF-06260182 (N=5, 14) | 60.36 ± 63 | 57.77 ± 66 |
Cmax is a measure of the plasma exposure to PF-06260182, a PF-02341066 metabolite. In this study, it is used to characterize the metabolite exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
| ng/mL | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D1 PF-06260182 (N=7, 19) | 2.625 ± 49 | 2.087 ± 63 |
| C1D15 PF-06260182 (N=5, 14) | 7.093 ± 54 | 6.508 ± 63 |
Molecular weight adjusted PF-06260182-to-PF-02341006 ratio of AUCtau is a measure of how much PF-02341066 (parent drug) was converted to the metabolite PF-06260182 after PF-02341066 dosing. In this study, it is used to characterize the metabolite-to-parent ratio exposure after a single dose (Cycle 1 Day 1) and multiple doses (Cycle 1 Day 15) of PF-02341066 were administered in combination of Erlotinib.
| Ratio | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D1 (N=7, 19) | 0.02748 ± 23 | 0.03395 ± 45 |
| C1D15 (N=5, 14) | 0.02574 ± 27 | 0.03258 ± 31 |
AUCtau is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).
| ng*hr/mL | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D-1 Erlotinib Alone (N=7,19) | 23490 ± 31 | 26880 ± 39 |
| C1D1 Erlotinib+Crizotinib Single Dose (N=7,19) | 26520 ± 25 | 30040 ± 39 |
| C1D15 Erlotinib+Crizotinib Multiple Doses (N=5,14) | 41770 ± 27 | 38910 ± 49 |
Cmax is a measure of the plasma exposure to erlotinib. In this study, it is used to characterize erlotinib exposure after multiple doses of erlotinib were administered alone (Day -1) and in combination of PF-02341066 (Cycle 1 Day 1 and Day 15).
| ng/mL | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| C1D-1 Erlotinib Alone (N=7,19) | 1593 ± 26 | 1797 ± 36 |
| C1D1 Erlotinib+Crizotinib Single Dose (N=7,19) | 1452 ± 21 | 1723 ± 38 |
| C1D15 Erlotinib+Crizotinib Multiple Doses (N=5,14) | 2546 ± 24 | 2346 ± 43 |
Apparent oral Clearance is a measure of combination of the rate at which a drug is removed from the blood (CL) and the bioavailability (F) after oral dose. In this study, it is used to characterize erlotinib CL/F after multiple doses in combination with PF-02341066 (Cycle 1 Day 15).
| L/hr | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Erlotinib Apparent Oral Clearance (CL/F) (Phase 1) | 2.395 ± 27 | 2.572 ± 49 |
Ratio of adjusted means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.
| Ratio in percentage | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Ratio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1) | 184.80 ± 40 | 149.41 ± 43 |
Ratio of adjusted means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) is a measure of the plasma exposure to erlotinib after erlotinib dosing with crizotinib compared with that after erlotinib dosing alone. In this study, it is used to characterize the effect magnitude of crizotinib on the erlotinib exposure after combinational use of crizotinib and erlotinib.
| Ratio in percentage | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Ratio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1) | 160.15 ± 49 | 134.60 ± 27 |
Time in weeks from phase 1 randomization to first documentation of objective disease progression or death due to any cause. Progression-Free Survival was calculated as (first event date minus randomization date plus 1) divided by 7.02. Tumor progression was determined from oncologic assessment data (where data meet the criteria for PD), or from AE data (where the outcome was "Death"; date of death reported in notice of death was used).
No measurements were reported for this outcome.
Median duration (50 percent \[%\]) of tumor response. Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.
No measurements were reported for this outcome.
Percentage of participants during phase 1 with objective response based assessment of confirmed CR or confirmed PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.
| percentage of participants | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Percentage of Participants With Objective Response (Phase 1) | 14.3 (0.4 to 57.9) | 5.6 (0.1 to 27.3) |
Levels of soluble protein biomarker c-MET was analyzed at Baseline and at Day 50.
| nanogram per milliliter (ng/mL) | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Baseline | 1560.0 ± NA | 1454.6 ± 303.93 |
| C3D1 0 Hour | 1870.0 ± NA | 1525.9 ± 442.01 |
| C3D1 6 Hour | 1660.0 ± NA | 1600.0 ± 369.05 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Median duration (50%) of tumor response. DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.
No measurements were reported for this outcome.
Percentage of participants during phase 2 with confirmed CR, confirmed PR or SD according to RECIST 1.1. Also known as Disease Control Rate (DCR). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions. SD: neither sufficient shrinkage or increase to qualify for PR or PD.
No measurements were reported for this outcome.
Percentage of participants during phase 2 with objective response based assessment of confirmed CR or confirmed PR according to RECIST (1.1). Confirmed responses: persist on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of nontarget disease. No new lesions.
No measurements were reported for this outcome.
Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.
No measurements were reported for this outcome.
Phase 2 EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
No measurements were reported for this outcome.
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, neuropathy, alopecia, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.
No measurements were reported for this outcome.
Plasma concentration of PF-02341066 and erlotinib when administered in combination during phase 2
No measurements were reported for this outcome.
Plasma concentration of erlotinib when administered as a single agent during phase 2
No measurements were reported for this outcome.
Tumor tissue samples collected for molecular profiling were to be analyzed to assess Kirsten rat sarcoma (KRAS) mutations, mutations, amplification and expression of Epidermal Growth Factor Receptor (EGFR) and c-Met, and echinoderm microtubule-associated protein-like 4-anaplastic large cell receptor kinase (EML4-ALK) fusion in tumors.
No measurements were reported for this outcome.
MTD: the combination dose level of PF-02341066 and erlotinib in which 0/6 or 1/6 participants experienced DLT after 28 days of treatment (Cycle 1) with the next higher dose level having at least 2/3 or 2/6 participants with DLT during Cycle 1 of treatment.
| mg | All Treated Participants (Phase 1) |
|---|---|
| PF-02341066 (BID) | 150 |
| Erlotinib (QD) | 100 |
If no more than 1/6 participants presented with a DLT during Cycle 1 at the MTD, then this dose level was considered the RP2D. If \>1/6 participants experienced a DLT, then the previous lower level was considered the MTD and RP2D.
| mg | All Treated Participants (Phase 1) |
|---|---|
| PF-02341066 (BID) | 150 |
| Erlotinib (QD) | 100 |
Collected over Up to 28 days after the last dose of study treatment (up to approximately 20 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-02341066 (200 mg) and Erlotinib (100 mg) | — | 2/7 (28.6%) | 7/7 (100%) |
| PF-02341066 (150 mg) and Erlotinib (100 mg) | — | 8/20 (40%) | 19/20 (95%) |
| Event | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| Disease progressionGeneral disorders | 0/7 | 4/20 |
| OesophagitisGastrointestinal disorders | 1/7 | 0/20 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/7 | 0/20 |
| PneumoniaInfections and infestations | 0/7 | 2/20 |
| Deep vein thrombosisVascular disorders | 0/7 | 2/20 |
| PancytopeniaBlood and lymphatic system disorders | 0/7 | 1/20 |
| Abdominal painGastrointestinal disorders | 0/7 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 1/20 |
| Viral infectionInfections and infestations | 0/7 | 1/20 |
| DehydrationMetabolism and nutrition disorders | 0/7 | 1/20 |
| Event | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/7 | 16/20 |
| Dry skinSkin and subcutaneous tissue disorders | 5/7 | 4/20 |
| FatigueGeneral disorders | 3/7 | 14/20 |
| RashSkin and subcutaneous tissue disorders | 4/7 | 13/20 |
| Decreased appetiteMetabolism and nutrition disorders | 3/7 | 12/20 |
| VomitingGastrointestinal disorders | 4/7 | 8/20 |
| NauseaGastrointestinal disorders | 3/7 | 11/20 |
| PainGeneral disorders | 2/7 | 0/20 |
| Rash pustularInfections and infestations | 2/7 | 0/20 |
| HypokalaemiaMetabolism and nutrition disorders | 2/7 | 0/20 |
| Age, Customized(participants) | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) | Total |
|---|---|---|---|
| 18 to 44 years | 1 | 0 | 1 |
| 45 to 64 years | 5 | 11 | 16 |
| greater than or equal to (≥) 65 | 1 | 9 | 10 |
| Sex: Female, Male(Participants) | PF-02341066 (200 mg) and Erlotinib (100 mg) | PF-02341066 (150 mg) and Erlotinib (100 mg) | Total |
|---|---|---|---|
| Female | 6 | 13 | 19 |
| Male | 1 | 7 | 8 |
The record gives a start of Jan 2010, a primary completion of Dec 2011 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib
Carcinoma, Non-Small-Cell Lung →